Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

MediciNova Inc

MNOV ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.41

▲ +0.00%

Market Cap $69.65M · Vol 14.34K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$69.65M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

-6.25%

YoY

RSI (14)

13.73

Momentum

Beta

0.68

vs Market

52W High

$3.89

63.75% below

52W Low

$1.17

20.51% above

Volume

14.34K

Avg 125.80K

P/B

1.55

Price-to-book

ROE

N/A

Return on equity

Free Float

97.14%

Public shares

Shariah Compliance8 STANDARDS

✗ MediciNova Inc (MNOV) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MNOV pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.76%

-51.38%

+6.02%

+0.00%

YTD

+7.63%

+15.57%

-27.69%

-61.48%

Financials & Valuation

TTM · Annual

Total Revenue	$409.66K
Net Income	$-11,997,960.00
Revenue Growth (YoY)	+240.60%
Gross Margin	7.58%
Operating Margin	-3,242.47%
Net Profit Margin	-2,928.78%
ROE	N/A
ROA · ROIC	-23.63% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	156.89
P/B	1.55
P/FCF	N/A
EPS Growth	-6.25%
Outstanding Shares	49.40M

Technical Indicators

50-Day SMA	$1.78
200-Day SMA	$1.52
RSI (14)	13.73
Beta	0.68
52-Week High	$3.89
52-Week Low	$1.17

Volume Today	14.34K
Avg Daily Volume (30D)	125.80K
Relative Volume	0.11x
Volatility (10D)	30.14
Volatility (30D)	149.00
Free Float	97.14%

Analyst Consensus

BUY

Current Price $1.41

Mean Target $8.25

52W Low$1.17 52W High$3.89

Current

Target

$1.17 $3.89

Current Analyst target

+485.11% upside potential · 4 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SNG8P4

ISINUS58468P2065

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.